5/2
07:30 am
ntla
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Low
Report
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
4/29
07:36 am
ntla
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 [Yahoo! Finance]
Medium
Report
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 [Yahoo! Finance]
4/29
07:30 am
ntla
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Medium
Report
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
4/25
12:46 pm
ntla
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
Low
Report
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
4/25
11:44 am
ntla
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/23
01:33 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
4/14
06:04 am
ntla
2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]
Low
Report
2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]
4/6
09:16 am
ntla
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]
3/25
01:40 pm
ntla
Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]
Low
Report
Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]
3/19
03:09 pm
ntla
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]
Low
Report
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]
3/18
07:42 am
ntla
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]
3/18
07:30 am
ntla
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Medium
Report
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
3/9
09:53 am
ntla
Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]
Low
Report
Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]
3/6
10:45 am
ntla
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
Low
Report
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
2/29
12:50 pm
ntla
Intellia Therapeutics Is On The Move [Seeking Alpha]
Low
Report
Intellia Therapeutics Is On The Move [Seeking Alpha]
2/29
06:06 am
ntla
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now [Yahoo! Finance]
Low
Report
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now [Yahoo! Finance]
2/28
11:25 am
ntla
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
Neutral
Report
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
2/27
11:22 am
ntla
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average [Yahoo! Finance]
Medium
Report
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average [Yahoo! Finance]
2/25
08:19 am
ntla
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
2/24
07:27 am
ntla
Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
2/23
01:07 pm
ntla
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update [Yahoo! Finance]
Low
Report
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update [Yahoo! Finance]
2/23
12:34 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/23
12:08 pm
ntla
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? [Yahoo! Finance]
2/23
10:12 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $72.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $72.00 to $73.00. They now have a "buy" rating on the stock.
2/23
09:36 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $32.00 price target on the stock, down previously from $136.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $32.00 price target on the stock, down previously from $136.00.